In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Resverlogix Plays Up Importance Of New Study After Missing Phase II Endpoint

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Resverlogix Corp. says it is keeping its faith in RVX-208 – a cholesterol drug designed to improve HDL function – despite missing a primary efficacy endpoint in the Phase II ASSERT trial, facing questions over a newly seen liver signal, and suffering a major blow to its stock price.
Advertisement

Related Content

Debut Of Merck's Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed
Resverlogix Thinks RVX-208 Can Succeed At Reducing Arterial Plaque Where Pfizer's Torcetrapib Failed

Topics

Advertisement
UsernamePublicRestriction

Register

PS004626

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel